End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2021 - 2028

Report Overview 

The global end stage renal disease market size was valued at USD 74.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.7% from 2021 to 2028. The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe. People suffering from diabetes and ESRD are prone to COVID-19 complications when compared to healthy individuals. Each country is taking care to ensure the safety of patients amid the crisis. The CDC, for instance, has issued guidelines and Interim Additional Guidance for Infection Prevention and Control (IPC) Recommendations for patients with suspected or confirmed COVID-19 in the outpatient hemodialysis facilities, to ensure the safety of hemodialysis patients.

Any condition that causes reduced kidney function leads to chronic kidney disease, which may develop over a period and lead to end-stage renal disease (ESRD) where kidneys can no longer function on their own. It is also termed kidney failure. Factors contributing to the formation of end stage renal disease are hypertension, diabetes, smoking, and the geriatric population. The most common cause is diabetes, whereas hypertension (high blood pressure) is the second most frequent cause of ESRD. The treatment of ESRD/CKD includes kidney transplantation or dialysis to stay alive.

Chronic Kidney Disease (CKD) is one of the major reasons for the increasing number of kidney failure patients. According to the National Kidney Foundation (NKD), approximately 10% of the global population suffers from CKD and millions die each year. As per the NKD estimation, the geriatric population suffers in developing countries, such as China and India. The number of patients continues to increase at a rate of 5-7% per year and receive treatment with a kidney transplant or dialysis to stay alive. Chronic kidney disease is estimated to be more common in women than men (15% vs 12%).

The increasing number of patients suffering from hypertension and diabetes are other factors fueling the overall market growth. Approximately, one-third of the population living with diabetes develop chronic kidney disease (CKD) and it is the most common cause of end-stage kidney disease. Hypertension is mainly caused due to high blood pressure, which significantly increases the risk of ESRD. According to the WHO facts 2019, around 1.13 billion people worldwide have hypertension. From 2014-2016, diabetes and hypertension were responsible for nearly 75% of kidney failure. Diabetes is the primary cause of advanced kidney disease, followed by hypertension, which is estimated to affect around 1 billion individuals globally. Thus, the increasing number of patients suffering from hypertension and diabetes are majorly driving the market.

Regions such as Africa, China, the Rest of Asia Pacific, the U.S., Taiwan, Japan, Germany, France, and Belgium have witnessed the highest prevalence of ESRD in recent years. As per the estimation of the Centers for Disease Control and Prevention (CDC) report 2016, in the U.S., around 125,000 people received treatment for end stage kidney disease (ESRD), whereas approximately 726,000 people were on dialysis or living with a kidney transplant.

Furthermore, it is reported that around 80 million people, which is around 1 in 3 American adults, are at risk of chronic kidney disease and it is the ninth leading cause of death in the U.S. Similarly, as per the report published by the NKF in 2017, it is estimated that the number of cases of renal failure will increase, especially in developing countries, such as China and India, in the elderly people, since the geriatric population is more prone to renal problems. The number of patients continues to increase at a rate of 5-7% per year and receive treatment with a kidney transplant or dialysis to stay alive. Therefore, such a high prevalence of ESRD is anticipated to boost the market growth over the forecast period.

The increasing incidence of renal failure in the developed and developing countries has driven the launch of technologically advanced products in the market. For instance, in February 2014, the first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 were approved by the U.S. FDA. This innovation is intended to obtain satisfactory and effective results from kidney failure patients. Thus, technological advancement in the treatment of renal failure is another factor expediting the overall market growth.

Treatment Insights

The dialysis segment dominated the ESRD market with a share of 81.9% in 2020. Dialysis is more convenient and easier to obtain for a patient with ESRD and the whole process can be done at a dialysis center or at home. Moreover, patients don’t have to depend on donor organs, which are available in a very limited number compared to dialysis equipment. Patients in developing, highly populous, or low-income countries can only obtain dialysis as compared to transplantation procedures. Thus, benefits offered by dialysis are expected to fuel the segment growth.

Moreover, growing awareness about various kidney failure diseases and unhealthy lifestyle are other factors driving the segment. DaVita Inc., a public community, and other related organizations are committed to raise global awareness regarding kidney diseases. These organizations arrange awareness education programs, such as kidney smart classes, in which kidney care experts provide education about the causes of kidney diseases, lifestyle choices, CKD basics, and healthy diets as well as nutrition information. The National Institute of Health (NIH) has declared the month of March as National Kidney Month in order to help raise awareness regarding kidney diseases. Thus, the presence of numerous awareness initiatives is expected to result in the growth of patients willing to test for kidney failure. A growing patient population with chronic kidney disease shall therefore opt for peritoneal dialysis or hemodialysis that will further increase the demand for ESRD treatment.

Regional Insights

Asia Pacific dominated the ESRD market with a share of 37.3% in 2020. This is attributed to the increasing healthcare spending, rising government initiatives, awareness campaigns regarding Chronic Kidney Disease (CKD), technologically enhanced products, and the presence of newly-established state of the art healthcare facilities in the region. High blood pressure and diabetes are the major risks for developing kidney disease. The Asia Pacific is estimated to have the largest population of diabetics and hypertension patients worldwide, closely followed by Africa.

The Asia Pacific region is expected to expand at the highest CAGR during the forecast period due to factors such as growth in the aging population, lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability. The Middle East and Africa is estimated to closely follow Asia Pacific in terms of CAGR. The African-Middle East ethnicity has been observed to be the most prone to CKD among the global population. The incidence rate of CKD among African-Middle Eastern countries stands at 18-23% of the total population, which is significantly higher than the global population.

Key Companies & Market Share Insights

The key market players are focusing on the launch of innovative types of products and accessories, growth strategies, and technological advancements. For instance, in October 2019, Fresenius Medical Care has received a breakthrough device designation by the U.S. FDA for its new hemodialysis machine that aims to stop blood clotting without the use of any medication. Additionally, few key players are introducing technologically advanced products to achieve a competitive advantage in the industry. Advancements in the ESRD devices market are anticipated to boost the market growth over the forecast period. Some prominent players in the global end stage renal disease market include:

• Nipro Corporation

• Fresenius Medical Care AG & Co. KGaA

• Baxter International, Inc.

• Medtronic Plc

• B. Braun Melsungen AG

• BD

• Asahi Kasei Medical Co., Ltd.

• Cantel Medical

• Nikkiso Co., Ltd.

• JMS Co. Ltd.

End Stage Renal Disease Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global end stage renal disease market report on the basis of treatment and region:

• Treatment Outlook (Revenue, USD Million, 2016 - 2028)

  • Transplant

  • Dialysis

    • Peritoneal Dialysis

    • Hemodialysis

    • Wearable Artificial Kidney

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE